STOCK TITAN
  1. Home
  2. Sec-filings
  3. FENC
  4. [Form 4] FENNEC PHARMACEUTICALS INC. Insider Trading Activity

Fennec CMO sells 12,000 shares at $12.18 each

FENNEC PHARMACEUTICALS INC.

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. (FENC) reported insider activity by Chief Medical Officer Pierre Sargis Sayad on 2026-08-31. He acquired 168 common shares at $0.00 per share upon release of restrictions from a prior award, and sold 12,000 previously vested restricted and performance shares at $12.18 per share. Net activity reflects a larger sale than acquisition, and resulting share holdings were not stated.

Positive

  • None.

Negative

  • None.
Insider Sayad Pierre Sargis
Role Chief Medical Officer
Sold 12,000 shs ($146K)
Type Security Shares Price Value
Grant/Award Common Shares F1 168 $0.00 $0.00
Sale Common Shares F2 12,000 $12.18 $146K
Holdings After Transaction: Common Shares — 9,519 shares (Direct)
Footnotes (2)
  1. F1. Represents shares released from restriction from shares awarded 3/28/2025.
  2. F2. Represents sale of previously vested restricted shares and vested performance shares.
Shares acquired 168 common shares Released from restriction from shares awarded 3/28/2025 on 2026-08-31
Acquisition price per share $0.00 per share Shares released from restriction on 2026-08-31
Shares sold 12,000 common shares Sale of previously vested restricted and performance shares on 2026-08-31
Sale price per share $12.18 per share Open-market or private sale on 2026-08-31
Net shares sold 12,000 shares Net-sell direction from transaction summary
restricted shares financial
"Represents sale of previously vested restricted shares and vested performance"
Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.
performance shares financial
"Represents sale of previously vested restricted shares and vested performance"
Performance shares are a type of company stock given to executives or employees that only become theirs if the company meets specific goals, like hitting certain profits or growth targets. They motivate leaders to work toward the company’s success, because their additional shares depend on achieving these results.
Grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition"

FAQ

What insider transactions did FENC report for Pierre Sargis Sayad on August 31, 2026?
On 2026-08-31, Chief Medical Officer Pierre Sargis Sayad acquired 168 common shares at $0.00 per share from a restriction release and sold 12,000 common shares at $12.18 per share, consisting of previously vested restricted and performance shares.

How many FENC shares did the insider sell in this Form 4 filing?
Pierre Sargis Sayad sold 12,000 common shares of FENNEC PHARMACEUTICALS INC. on 2026-08-31. The filing notes these were previously vested restricted shares and vested performance shares, sold at a price of $12.18 per share.

What shares did the insider acquire in the FENC Form 4 filing?
The insider acquired 168 common shares of FENNEC PHARMACEUTICALS INC. at $0.00 per share on 2026-08-31. A footnote explains these represent shares released from restriction from shares originally awarded on 3/28/2025.

Were the FENC insider transactions under a Rule 10b5-1 trading plan?
No. The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed (aff_10b5_one is false), and the footnotes do not state that the transactions were made pursuant to a Rule 10b5-1 trading plan.

Does the FENC Form 4 show the insider’s holdings after these transactions?
No. The Form 4 lists the transactions but leaves the total shares following the transaction field blank for both entries, so the reporting person’s post-transaction holdings are not provided in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sayad Pierre Sargis
(Last)(First)(Middle)
C/O FENNEC PHARMACEUTICALS, INC.
PO BOX 13628, 68 TW ALEXANDER DRIVE
(Street)
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares(1)08/31/2026A168A$021,519D
Common Shares(2)08/31/2026S12,000D$12.189,519D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares released from restriction from shares awarded 3/28/2025.
2. Represents sale of previously vested restricted shares and vested performance shares.
/s/ Pierre Sayad08/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR